

# Medical Drug Clinical Criteria

**Subject:** Elfabrio (pegunigalsidase alfa-iwxj)

**Document #:** CC-0241

**Status:** New

**Publish Date:** 07/11/2023

**Last Review Date:** 06/12/2023

## Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical Criteria](#)

[Document History](#)

## Overview

This document addresses the clinical indications for Elfabrio (pegunigalsidase alfa-iwxj), a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme. Elfabrio (pegunigalsidase alfa-iwxj) is an enzyme replacement therapy (ERT) approved for the treatment of individuals with a lipid storage disorder called Fabry disease.

Fabry disease is an X-linked lysosomal (lipid) storage disorder related to a deficiency of the enzyme alpha-galactosidase A ( $\alpha$ -Gal-A, also known as ceramide trihexosidase) required to metabolize lipids. Signs and symptoms of Fabry disease include burning sensations in the arms and legs (that worsens with exercise and hot weather), small, non-cancerous, raised reddish-purple blemishes on the skin, and clouding of the corneas. Other symptoms include decreased sweating, fever, and gastrointestinal difficulties. Lipid storage may lead to breathing and digestive problems, impaired circulation, and increased risk of cardiomyopathy, cerebrovascular accidents, and renal failure.

The American College of Medical Genetics (ACMG) (2011) and National Society of Genetic Counselors (NSGC) (2013) recommend screening for deficient  $\alpha$ -Gal-A enzyme activity in males followed by confirmatory galactosidase alpha (GLA) gene sequencing. As  $\alpha$ -Gal-A activity is unreliable in females, GLA gene sequencing should be performed for a confirmatory diagnosis.

ACMG states ERT is the standard of care for symptomatic individuals as it has shown improvements in the rate of renal dysfunction, pulmonary and gastrointestinal symptoms.

Elfabrio has a black box warning for hypersensitivity reactions, including anaphylaxis, and recommendations for appropriate medical support to be readily available during administration (i.e., cardiopulmonary resuscitation equipment). If severe hypersensitivity occurs, immediate discontinuation is recommended. A desensitization procedure may also be considered in these individuals.

## Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Elfabrio (pegunigalsidase alfa-iwxj)

Initial requests for Elfabrio (pegunigalsidase alfa-iwxj) may be approved if the following criteria are met:

- I. Documentation is provided that individual has a diagnosis of Fabry disease as defined with either of the following (ACMG, NSGC):
  - A. Documentation of complete deficiency or less than 5% of mean normal alpha-galactosidase A ( $\alpha$ -Gal A) enzyme activity in leukocytes, dried blood spots, or serum (plasma) analysis; **OR**
  - B. Documented galactosidase alpha gene mutation by gene sequencing;

## **AND**

- II. The individual to be treated has one or more symptoms, or physical findings attributable to Fabry disease (ACMG), including, but not limited to:
- A. Burning pain in the extremities (acroparesthesias); OR
  - B. Cutaneous vascular lesions (angiokeratomas); OR
  - C. Corneal verticillata (whorls); OR
  - D. Decreased sweating (anhidrosis or hypohidrosis); OR
  - E. Personal or family history of exercise, heat, or cold intolerance; OR
  - F. Personal or family history of kidney failure.

Continuation requests for Elfabrio (pegunigalsidase alfa-iwxj) may be approved if the following criteria are met:

- I. Individual has had a positive therapeutic response to treatment.

Elfabrio (pegunigalsidase alfa-iwxj) may not be approved for the following:

- I. Individual is using in combination with migalastat (Galafold) or Fabrazyme (agalsidase beta); OR
- II. When the above criteria are not met and for all other indications.

## **Quantity Limits**

### **Elfabrio (pegunigalsidase alfa-iwxj) Quantity Limits**

<u>Drug</u>	<u>Limit</u>
Elfabrio (pegunigalsidase alfa-iwxj) 20 mg/10 mL vial	1 mg/kg every two weeks

## **Coding**

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### **HCPSC**

- J3490 Unclassified drugs (when specified as [Elfabrio] (pegunigalsidase alfa-iwxj))
- J3590 Unclassified biologics (when specified as [Elfabrio] (pegunigalsidase alfa-iwxj))

### **ICD-10 Diagnosis**

All diagnoses pend

## **Document History**

New: 06/12/2023

Document History:

- 06/12/2023 – Select Review: Add new clinical criteria document for Elfabrio. Coding Reviewed: Added HCPSC J3490, J3590. All diagnoses pend.

## **References**

1. Biegstraaten M, Arngimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet J Rare Dis.* 2015; 10:36. Available at

[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383065/pdf/13023\\_2015\\_Article\\_253.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383065/pdf/13023_2015_Article_253.pdf). Accessed: June 6, 2023.

2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 6, 2023.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. *J Inher Metab Dis*. 2011;34(2):509-514. Accessed June 6, 2023.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
6. Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors (NSGC). *J Genet Couns*. 2013;22(5):555-564. Accessed June 6, 2023.
7. Ortiz A, Germain D, Desnick R, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Gen Metab*. 2018;123(4):416-427. Accessed on June 6, 2023.
8. Schiffmann R, Hughes D, Linthorst G, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney Intl*. 2017;91:284-293. Accessed June 6, 2023.
9. Wang RY, Bodamer OA, Watson MS, Wilcox WR; American College of Medical Genetics (ACMG) Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. *Genet Med*. 2011;13(5):457-484. Accessed June 6, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association